Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

John R. Lozada; Andrew Elliott; Mark G. Evans; James Wacker; Kathleen M. Storey; Emily A. Egusa; Nicholas A Zorko; Akhilesh Kumar; Anthony Crymes; Elisabeth I. Heath; Benedito A. Carneiro; Heloisa P. Soares; Frank M Cichocki; Jeffrey S Miller; Emil Lou; Himisha Beltran; Emmanuel S. Antonarakis; Charles Ryan; Justin Hwang

doi:10.1158/2767-9764.crc-24-0501

Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

John R. Lozada
, Andrew Elliott
, Mark G. Evans
, James Wacker
, Kathleen M. Storey
, Emily A. Egusa
, Nicholas A Zorko
, Akhilesh Kumar
, Anthony Crymes
, Elisabeth I. Heath
, Benedito A. Carneiro
, Heloisa P. Soares
, Frank M Cichocki
, Jeffrey S Miller
, Emil Lou
, Himisha Beltran
, Emmanuel S. Antonarakis
, Charles Ryan
, Justin Hwang

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

SIGNIFICANCE: DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.

Original language	English (US)
Pages (from-to)	318-326
Number of pages	9
Journal	Cancer Research Communications
Volume	5
Issue number	2
DOIs	https://doi.org/10.1158/2767-9764.crc-24-0501
State	Published - Feb 1 2025

Bibliographical note

Publisher Copyright:
©2025 The Authors; Published by the American Association for Cancer Research.

Keywords

Gene Expression Regulation, Neoplastic
Humans
Intracellular Signaling Peptides and Proteins/metabolism
Membrane Proteins/metabolism
Molecular Targeted Therapy/methods
Neoplasms/metabolism
Neuroendocrine Tumors/metabolism

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/2767-9764.crc-24-0501

https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-24-0501/3537536/crc-24-0501.pdfLicense: CC BY

Find It

Find It at U of M Libraries

Cite this

Lozada, J. R., Elliott, A., Evans, M. G., Wacker, J., Storey, K. M., Egusa, E. A., Zorko, N. A., Kumar, A., Crymes, A., Heath, E. I., Carneiro, B. A., Soares, H. P., Cichocki, F. M., Miller, J. S., Lou, E., Beltran, H., Antonarakis, E. S., Ryan, C., & Hwang, J. (2025). Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting. Cancer Research Communications, 5(2), 318-326. https://doi.org/10.1158/2767-9764.crc-24-0501

Lozada, JR, Elliott, A, Evans, MG, Wacker, J, Storey, KM, Egusa, EA, Zorko, NA , Kumar, A, Crymes, A, Heath, EI, Carneiro, BA, Soares, HP, Cichocki, FM , Miller, JS , Lou, E, Beltran, H, Antonarakis, ES , Ryan, C & Hwang, J 2025, 'Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting', Cancer Research Communications, vol. 5, no. 2, pp. 318-326. https://doi.org/10.1158/2767-9764.crc-24-0501

@article{bb44d053875f4326bdd4ba4ec1a263a8,

title = "Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting",

abstract = "SIGNIFICANCE: DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.",

keywords = "Gene Expression Regulation, Neoplastic, Humans, Intracellular Signaling Peptides and Proteins/metabolism, Membrane Proteins/metabolism, Molecular Targeted Therapy/methods, Neoplasms/metabolism, Neuroendocrine Tumors/metabolism",

author = "Lozada, \{John R.\} and Andrew Elliott and Evans, \{Mark G.\} and James Wacker and Storey, \{Kathleen M.\} and Egusa, \{Emily A.\} and Zorko, \{Nicholas A\} and Akhilesh Kumar and Anthony Crymes and Heath, \{Elisabeth I.\} and Carneiro, \{Benedito A.\} and Soares, \{Heloisa P.\} and Cichocki, \{Frank M\} and Miller, \{Jeffrey S\} and Emil Lou and Himisha Beltran and Antonarakis, \{Emmanuel S.\} and Charles Ryan and Justin Hwang",

note = "Publisher Copyright: {\textcopyright}2025 The Authors; Published by the American Association for Cancer Research.",

year = "2025",

month = feb,

day = "1",

doi = "10.1158/2767-9764.crc-24-0501",

language = "English (US)",

volume = "5",

pages = "318--326",

journal = "Cancer Research Communications",

issn = "2767-9764",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

AU - Lozada, John R.

AU - Elliott, Andrew

AU - Evans, Mark G.

AU - Wacker, James

AU - Storey, Kathleen M.

AU - Egusa, Emily A.

AU - Zorko, Nicholas A

AU - Kumar, Akhilesh

AU - Crymes, Anthony

AU - Heath, Elisabeth I.

AU - Carneiro, Benedito A.

AU - Soares, Heloisa P.

AU - Cichocki, Frank M

AU - Miller, Jeffrey S

AU - Lou, Emil

AU - Beltran, Himisha

AU - Antonarakis, Emmanuel S.

AU - Ryan, Charles

AU - Hwang, Justin

PY - 2025/2/1

Y1 - 2025/2/1

N2 - SIGNIFICANCE: DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.

AB - SIGNIFICANCE: DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological correlates of DLL3 expression in both neuroendocrine and non-neuroendocrine cancers. Our findings may stimulate the development and application of DLL3-targeted therapies, as well as other precision therapies, in neuroendocrine cancers and beyond.

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Intracellular Signaling Peptides and Proteins/metabolism

KW - Membrane Proteins/metabolism

KW - Molecular Targeted Therapy/methods

KW - Neoplasms/metabolism

KW - Neuroendocrine Tumors/metabolism

UR - https://www.scopus.com/pages/publications/85219495826

UR - https://www.scopus.com/pages/publications/85219495826#tab=citedBy

U2 - 10.1158/2767-9764.crc-24-0501

DO - 10.1158/2767-9764.crc-24-0501

M3 - Article

C2 - 39874041

AN - SCOPUS:85219495826

SN - 2767-9764

VL - 5

SP - 318

EP - 326

JO - Cancer Research Communications

JF - Cancer Research Communications

IS - 2

ER -

Expression Patterns of DLL3 across Neuroendocrine and Non-neuroendocrine Neoplasms Reveal Broad Opportunities for Therapeutic Targeting

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this